Clinical Research Directory

SCREENING Inclusion Criteria: * Age 30 years or older at the time of consent * Either: 1. Self-identify as Black and/or African American OR 2. First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenström's Macroglobulinemia * Capable and willing to provide informed consent. NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately * Reside in Charlotte, NC, or the surrounding area, based on self-report SCREENING Exclusion Criteria: * Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS. LONGITUDINAL Inclusion Criteria: * Test positive for monoclonal gammopathy during screening portion of the study * Consent to the longitudinal portion of the study LONGITUDINAL Exclusion Criteria: * The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.